BBOT vs IMRX
BBOT: BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including KRAS-driven lung and pancreatic cancers. IMRX: Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors, a novel class of MEK/MAPK inhibitors designed to improve durability and tolerability in cancer by reducing toxicity and resistance through cadenced signaling inhibition.
Side-by-side fundamentals
| Metric | BBOT | IMRX | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $8.78 | $4.46 | |
| Market cap as of 2026-08-08 | $703M | $292M | |
| Net margin as of 2026-08-08 | n/a | -9610.0% | |
| Gross margin as of 2026-08-08 | n/a | +28.0% | |
| Operating margin as of 2026-08-08 | n/a | -9778.0% | |
| ROE as of 2026-08-08 | -35.2% | -31.9% | IMRX higher |
| ROA as of 2026-08-08 | -32.2% | -29.9% | IMRX higher |
| Debt / equity as of 2026-08-08 | 0.00 | 0.00 | Tie |
| Beta as of 2026-08-08 | 0.38 | 0.31 | |
| 1-year return as of 2026-08-06 close | -11.2% | +26.7% | IMRX higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.